Welcome to


What if a Pap test shows an abnormal result and an HPV test comes back positive at routine cervical cancer screening? These tests may indicate the presence of cancer, but often turn out to be a ‘false alarm’. Time-consuming examinations may then follow for further clarification, such as a colposcopy and, if tissue changes are seen, biopsy. If the outcome of the biopsy further points to abnormalities, surgical procedures are often performed, sometimes turning out to be done unnecessarily.

Cervical cancer – Reliable diagnosis with only one cervical smear

Oncgnostics GmbH developed the GynTect® test in order to prevent patients from this stressful period of uncertainty surrounding abnormal cervical cancer screening and follow-up results, and to offer doctors a quick and reliable cervical cancer diagnosis. This non-invasive test, performed from just one cervical smear, examines the DNA of cells for changes that indicate cervical cancer and its preliminary stages.

The innovation of the GynTect® test is the reliable detection of DNA methylation originally found in cervical carcinoma tissue, i.e. the alteration of the genetic material of abnormal cells. Thus, a cervical cancer diagnosis can be confirmed with certainty in a very short time or, in the case of supposedly positive Pap tests, the all-clear can be given. In previous studies, GynTect® reliably detected all cervical carcinomas, reason why the GynTect® test should be used in cervical cancer screening.

Information for patients

Cervical cancer and its early detection

Cervical cancer – development and prevention

The Pap smear test at the gynaecologist for early detection of cervical cancer is routine for most women. If this routine is broken by an abnormal finding, the affected women are left with many questions in mind: What does an abnormal Pap smear result or a positive HPV test result mean? What are my options? The following page is intended to give women an overview on the topic cervical cancer.

Information for physicians

GynTect® in the gynaecology practice

GynTect® – Methylation marker for the detection of cervical cancer

For example: women in Germany may get tested with a Pap smear every year from the age of 20. More than 200,000 women in Germany receive a Pap III or Pap IIID cytology finding, but dysplasia of the cervix does not necessarily lead to the development of carcinoma. In addition to common diagnostic methods such as colposcopy, women also have other options for fast, safe, and non-invasive diagnosis: Learn more about GynTect®, the molecular in vitro test, here.

Information for laboratories

GynTect® – Analysis by Polymerase Chain Reaction

GynTect® – Detection of methylation markers by means of PCR

GynTect® is a molecular test for cervical carcinoma that is used in in vitro diagnosis. The test detects epigenetic changes characteristic for cancer cells. GynTect® biomarkers are detected by means of a polymerase chain reaction (PCR). GynTect® is a CE marked in vitro diagnostic product (CE IVD).

For GynTect®

we have determined epigenetic markers for the detection of cervical carcinoma. The principle of the test is based on the detection of DNA methylation in human gene regions. GynTect® is a non-invasive screening test for which a smear sample is sufficient.